Nuevo Usuario

Recordar Contraseña

Revisiones en Cáncer 00104 / http://dx.doi.org/10.20960/revcancer.00104

Resumen| PDF

Revisión

Presente y futuro de la terapia sistémica para las etapas tempranas e intermedias del carcinoma hepatocelular

Juan José Urquijo Ponce, Carlos Alventosa-Mateu

Prepublicado: 2025-09-01

Logo Descargas Número de descargas: 159 Logo Visitas Número de visitas: 47 Citas Citas: 0

Compártelo:

Los pacientes con carcinoma hepatocelular (CHC) que pueden beneficiarse de un tratamiento curativo (habitualmente, resección quirúrgica) presentan una supervivencia limitada debido a la elevada tasa de recurrencia tumoral posquirúrgica. La aparición de nuevas opciones terapéuticas dentro del tratamiento sistémico, con beneficios favorables en incremento de supervivencia en estadios avanzados del CHC, ha condicionado que se plantee su uso tanto en el estadio precoz del CHC como en los pacientes del estadio intermedio, que son inicialmente candidatos a tratamiento, curativo o como downstaging para lograr este objetivo. En este artículo realizamos una revisión de la evidencia de los resultados del tratamiento sistémico en este contexto, analizamos el impacto actual de esta estrategia terapéutica y valoramos su potencial papel en el presente y en el futuro de los pacientes con CHC en estadios precoz e intermedio.

Palabras Clave: Carcinoma hepatocelular. Tratamiento sistémico. Neoadyuvancia.

Descargar PDF

Bibliografía
Artículos Relacionados

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229-63.
DOI: 10.3322/caac.21834

Llovet JM, Willoughby CE, Singal AG, et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol 2023;20(8):487-503.
DOI: 10.1038/s41575-023-00754-7

Wolf E, Rich NE, Marrero JA, et al. Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. Hepatology 2021;73(2):713-25.
DOI: 10.1002/hep.31309

Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Prim 2016 2:16018.
DOI: 10.1038/nrdp.2016.18

Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76(3):681-93.
DOI: 10.1016/j.jhep.2021.11.018

Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 2025; Feb 20:S0923-7534(25)00073-0. Online ahead of print.

Sangro B, Argemi J, Ronot M, et al. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol 2025;82(2):315-74.
DOI: 10.1016/j.jhep.2024.08.028

Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-65.
DOI: 10.1097/HEP.0000000000000466

Nevola R, Ruocco R, Criscuolo L, et al. Predictors of early and late hepatocellular carcinoma recurrence. World J Gastroenterol 2023;29(8):1243-60.
DOI: 10.3748/wjg.v29.i8.1243

Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015;261(5):947-55.
DOI: 10.1097/SLA.0000000000000710

Zhu Y, Gu L, Chen T, et al. Factors influencing early recurrence of hepatocellular carcinoma after curative resection. J Int Med Res 2020;48(8):300060520945552.
DOI: 10.1177/0300060520945552

Xu XF, Xing H, Han J, et al. Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China. JAMA Surg 2019;154(3):209-17.
DOI: 10.1001/jamasurg.2018.4334

Chapman WC, García-Aroz S, Vachharajani N, et al. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. J Am Coll Surg 2017;224(4):610-21.
DOI: 10.1016/j.jamcollsurg.2016.12.020

Ravaioli M, Grazi GL, Piscaglia F, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008;8(12):2547-57.
DOI: 10.1111/j.1600-6143.2008.02409.x

Pinter M, Jain RK, Duda DG. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol 2021;7(1):113-23.
DOI: 10.1001/jamaoncol.2020.3381

Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2022;19(3):151-72.
DOI: 10.1038/s41571-021-00573-2

Schmid P, Cortes J, Dent R, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 2022;386(6):556-67.
DOI: 10.1056/NEJMoa2112651

Patel SP, Othus M, Chen Y, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388(9):813-23.
DOI: 10.1056/NEJMoa2211437

Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med 2022;386(21):1973-85.
DOI: 10.1056/NEJMoa2202170

Llovet JM, Pinyol R, Yarchoan M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol 2024;21(4):294-311.
DOI: 10.1038/s41571-024-00868-0

Urquijo-Ponce JJ, Alventosa-Mateu C, Latorre-Sánchez M, et al. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma. World J Gastroenterol 2024;30(19):2512-22.
DOI: 10.3748/wjg.v30.i19.2512

Vogel A, Grant RC, Meyer T, et al. Adjuvant and neoadjuvant therapies for hepatocellular carcinoma. Hepatology 2023;Dec 18. Online ahead of print.
DOI: 10.1097/HEP.0000000000000726

Hu L, Kong Y, Qiao Y, et al. Can adjuvant immune checkpoint inhibitors improve the long-term outcomes of hepatocellular carcinoma with high-risk recurrent factors after liver resection? A meta-analysis and systematic review. Front Oncol 2024;14:1374262
DOI: 10.3389/fonc.2024.1374262

Teng W, Wu T-C, et al. Hepatocellular carcinoma systemic treatment 2024 update: from early to advanced stage. Biomed J 2024;100815.
DOI: 10.1016/j.bj.2024.100815

Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat cancer 2021;2(9):891-903.
DOI: 10.1038/s43018-021-00234-4

Zhu XD, Huang C, Shen YH, et al. Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. Liver cancer 2021;10(4):320-9.
DOI: 10.1159/000514313

Zhang W, Hu B, Han J, et al. Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. Front Oncol 2021;11:747950
DOI: 10.3389/fonc.2021.747950

Pinato DJ, Cortellini A, Sukumaran A, et al. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer 2021;21(1):301
DOI: 10.1186/s12885-021-08033-x

Woei-A-Jin FJSH, Weijl NI, et al. Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study. Oncologist 2021;26(10):854-64.
DOI: 10.1002/onco.13901

Bouattour M, Fartoux L, Rosmorduc O, et al. BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)-From GERCOR IRC. JCO 2016;34(4):suppl.252.
DOI: 10.1200/jco.2016.34.4_suppl.252

Ming K, Xie W, Chen J, et al. Neo-adjuvant tislelizumab combined with lenvatinib treatment for resectable, recurrent hepatocellular carcinoma. JCO 2024;42(3):suppl.517.
DOI: 10.1200/JCO.2024.42.3_suppl.517

Marron TU, Fiel MI, Hamon P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. lancet Gastroenterol Hepatol 2022;7(3):219-29.
DOI: 10.1016/S2468-1253(21)00385-X

Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet (London, England) 2023;402(10415):1835-47.
DOI: 10.1016/S0140-6736(23)01796-8

Yopp A, Kudo M, Chen M et al. LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) frente a active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC). Ann Oncol 2024;35(Suppl.2):1-72.
DOI: 10.1016/j.annonc.2024.08.2279

Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16(13):1344-54.
DOI: 10.1016/S1470-2045(15)00198-9

Mao X, Duan X WD et al. Preliminary results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection. JCO 2024;42(3):suppl.494.
DOI: 10.1200/JCO.2024.42.3_suppl.494

Chen Y, Shen Y, Zhang M, et al. Adjuvant therapy with donafenib plus anti-PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study). JCO 2024;42(16):suppl.e16228.
DOI: 10.1200/JCO.2024.42.16_suppl.e16228

Wang J, Peng T, Liu C, et al. Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study. JCO 2024;42(16)suppl.e16.
DOI: 10.1200/JCO.2024.42.16_suppl.e16239

Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. lancet Gastroenterol Hepatol 2022;7(3):208-18.
DOI: 10.1016/S2468-1253(21)00427-1

Xia Y, Tang W, Qian X, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer 2022;10(4):e004656.
DOI: 10.1136/jitc-2022-004656

Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020;21(7):947-56.
DOI: 10.1016/S1470-2045(20)30224-2

Lv Z, Xiang X, Yong J, et al. Pembrolizumab in combination with LEnvatinib in participants with hepatocellular carcinoma before liver transplant as Neoadjuvant TherapY-PLENTY pilot study. Int J Surg 2024;110(10):6647-57.
DOI: 10.1097/JS9.0000000000001813

Tabrizian P, Marino R, Bhoori S, et al. Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma. JHEP reports Innov Hepatol 2024;7(2):101246.
DOI: 10.1016/j.jhepr.2024.101246

Tabrizian P, Holzner M, Ajmera V, et al. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study. J Hepatol 2025;82(3):512-22.
DOI: 10.1016/j.jhep.2024.09.003

Kudo M, Ren Z, Guo Y, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet (London, England) 2025;405(10474):203-15.
DOI: 10.1016/S0140-6736(24)02575-3

Sangro B, Kudo M, Erinjeri JP, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet (London, England) 2025;405(10474):216-32.
DOI: 10.1016/S0140-6736(24)02551-0

Guo C, Zhang J, Huang X, et al. Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatol Commun 2023;7(3):e0054.
DOI: 10.1097/HC9.0000000000000054

Nakazawa M, Fang M, Vong T, et al. Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC. Cancer Res Commun 2024;4(8):2123-32.
DOI: 10.1158/2767-9764.CRC-24-0151

Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol Off J Eur Soc Med Oncol 2018;29(8):1861-8.
DOI: 10.1093/annonc/mdy226

Li M, Bhoori S, Mehta N, et al. Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation. J Hepatol 2024;81(4):743-55.
DOI: 10.1016/j.jhep.2024.05.037

Sia D, Jiao Y, Martínez-Quetglas I, et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology 2017;153(3):812-26.
DOI: 10.1053/j.gastro.2017.06.007

Lucas MW, Versluis JM, Rozeman EA, et al. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. Nat Rev Clin Oncol 2023;20(6):408-22.
DOI: 10.1038/s41571-023-00760-3

Patel SP, Othus M, Chen Y, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388(9):813-23.
DOI: 10.1056/NEJMoa2211437

Marron TU, Galsky MD, Taouli B, et al. Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. Nat Med 2022;28(4):626-9.
DOI: 10.1038/s41591-022-01681-x

Jørgensen JT. The current landscape of the FDA approved companion diagnostics. Transl Oncol 2021;14(6).
DOI: 10.1016/j.tranon.2021.101063

Zhu AX, Abbas AR, De Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 2022;28(8):1599-611.
DOI: 10.1038/s41591-022-01868-2

Greten TF, Villanueva A, Korangy F, et al. Biomarkers for immunotherapy of hepatocellular carcinoma. Nat Rev Clin Oncol 2023;20(11):780-98.
DOI: 10.1038/s41571-023-00816-4

Chan YT, Zhang C, Wu J, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer 2024;23(1):189.
DOI: 10.1186/s12943-024-02101-z

Yarchoan M, Gane EJ, Marron TU, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nat Med 2024;30(4):1044-53.
DOI: 10.1038/s41591-024-02894-y